© The Financial Times Ltd 2016 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Feb 06, 2016, the consensus forecast amongst 24 polled investment analysts covering Kalbe Farma Tbk PT advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Nov 19, 2015. The previous consensus forecast advised that Kalbe Farma Tbk PT would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 22 analysts offering 12 month price targets for Kalbe Farma Tbk PT have a median target of 1,525, with a high estimate of 2,000 and a low estimate of 1,100. The median estimate represents a 15.09% increase from the last price of 1,325. View Full Financials
In 2014, Kalbe Farma Tbk PT reported a dividend of 19.00 IDR, which represents a 11.76% increase over last year. The 20 analysts covering the company expect dividends of 19.76 IDR for the upcoming fiscal year, an increase of 4.02%. View Full Financials
|Div growth (TTM)||+11.76 %|
On Oct 30, 2015, Kalbe Farma Tbk PT reported 3rd quarter 2015 earnings of 9.30 per share.
The next earnings announcement is expected on Mar 28, 2016. View Full Interim Financials
|Average growth rate||-4.97 %|
Kalbe Farma Tbk PT reported annual 2014 earnings of 44.00 per share on Mar 30, 2015.
The next earnings announcement from Kalbe Farma Tbk PT is expected the week of Mar 28, 2016. View Full Annual Financials
|Average growth rate||+12.64 %|
PT. Kalbe Farma Tbk. had 3rd quarter 2015 revenues of 4.41bn. This missed the 4.51bn consensus estimate of the 4 analysts following the company. This was 0.67% above the prior year's 3rd quarter results. View Full Interim Financials
|Average growth rate||+0.32 %|
PT. Kalbe Farma Tbk. had revenues for the full year 2014 of 17.37bn. This was 8.54% above the prior year's results. View Full Annual Financials
|Average growth rate||+14.39 %|